Journal Article

Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies

Chemaly, Elie R., Ramos-Kuri, Manuel, Meka, Sri Harika, Hajjar, Roger J., Lipskaia, Larissa, Salamanca-Buentello, Fabio

2021

Overview

The Ras family of small Guanosine Triphosphate (GTP)-binding proteins (G proteins) represents one of the main components of intracellular signal transduction required for normal cardiac growth, but is also critically involved in the development of cardiac hypertrophy and heart failure. The present review provides an update on the role of the H-, K- and N-Ras genes and their related pathways in cardiac diseases. We focus on cardiac hypertrophy and heart failure, where Ras has been studied the most. We also review other cardiac diseases, like genetic disorders related to Ras. The scope of the review extends from fundamental concepts to therapeutic applications. Although the three Ras genes have a nearly identical primary structure, there are important functional differences between them: H-Ras mainly regulates cardiomyocyte size, whereas K-Ras regulates cardiomyocyte proliferation. N-Ras is the least studied in cardiac cells and is less associated to cardiac defects. Clinically, oncogenic H-Ras causes Costello syndrome and facio-cutaneous-skeletal syndromes with hypertrophic cardiomyopathy and arrhythmias. On the other hand, oncogenic K-Ras and alterations of other genes of the Ras-Mitogen-Activated Protein Kinase (MAPK) pathway, like Raf, cause Noonan syndrome and cardio-facio-cutaneous syndromes characterized by cardiac hypertrophy and septal defects. We further review the modulation by Ras of key signaling pathways in the cardiomyocyte, including: (i) the classical Ras-Raf-MAPK pathway, which leads to a more physiological form of cardiac hypertrophy; as well as other pathways associated with pathological cardiac hypertrophy, like (ii) The SAPK (stress activated protein kinase) pathways p38 and JNK; and (iii) The alternative pathway Raf-Calcineurin-Nuclear Factor of Activated T cells (NFAT). Genetic alterations of Ras isoforms or of genes in the Ras-MAPK pathway result in Ras-opathies, conditions frequently associated with cardiac hypertrophy or septal defects among other cardiac diseases. Several studies underline the potential role of H- and K-Ras as a hinge between physiological and pathological cardiac hypertrophy, and as potential therapeutic targets in cardiac hypertrophy and failure. Graphic abstract Highlights The Ras (Rat Sarcoma) gene family is a group of small G proteins Ras is regulated by growth factors and neurohormones affecting cardiomyocyte growth and hypertrophy Ras directly affects cardiomyocyte physiological and pathological hypertrophy Genetic alterations of Ras and its pathways result in various cardiac phenotypes Ras and its pathway are differentially regulated in acquired heart disease Ras modulation is a promising therapeutic target in various cardiac conditions.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,Sociedad de Biología de Chile,BMC
• Subject: Amino acid sequence / Amino acids / Binding proteins / BIOLOGY / Biomedical and Life Sciences / Calcineurin / Cardiomyocytes / Cardiomyopathy / Cell Biology / Cell growth / Cell proliferation / Cellular signal transduction / Congestive heart failure / Coronary artery disease / Developmental Biology / G proteins / Gene expression / Genes / Genetic disorders / H-Ras gene / H-Ras protein / Health aspects / Heart / Heart enlargement / Hypertrophy / Isoforms / K-Ras gene / K-Ras protein / Kinases / Life Sciences / MAP kinase / Medical research / Medicine, Experimental / Membrane proteins / Microbiology / Mitogens / Mutation / Neurosciences / NF-AT protein / Noonan's syndrome / Pathological hypertrophy / Phosphorylation / Physiological aspects / Physiological hypertrophy / Physiology / Plant Sciences / Protein binding / Protein kinase / Protein kinases / Proteins / Raf protein / Ras pathway / Ras protein / Ras-opathies / Review / Reviews / Sarcoma / Signal transduction / T cells / Therapeutic applications / Therapeutic targets / Transcription factors / Transgenic animals